Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients

Abstract

We suggest that ELX/TEZ/IVA may improve fat-soluble vitamin absorption, specifically serum 25-hydroxyvitamin D. These results may lead to adjustments in vitamin supplementation in patients receiving cystic fibrosis transmembrane conductance regulator modulator therapy.